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quired crizotinib resistance whose adenocarcinoma re-
sponded to a second course of crizotinib following a drug 
holiday and chemotherapy with pemetrexed. This is the sec-
ond case report to suggest that retreatment with crizotinib 
is an option for patients with initial benefit from ALK inhibi-
tion.  © 2014 S. Karger AG, Basel 
 Introduction 
 The treatment of advanced non-small cell lung cancer 
(NSCLC) has dramatically changed over the last decade 
and has developed from an unspecific approach based on 
platinum doublet chemotherapy to a personalized, mo-
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 Abstract 
 The treatment of advanced non-small cell lung cancer 
(NSCLC) has dramatically changed over the last decade. It 
has developed from an unspecific approach based on plati-
num doublet chemotherapy to a personalized, molecularly 
targeted therapy. Crizotinib is a new tyrosine kinase inhibitor 
approved for the treatment of NSCLC with gene rearrange-
ment of EML4 and ALK. Despite good initial responses, pa-
tients treated with crizotinib relapse after an average of 10 
months. In this case report, we present a patient with ac-
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 Established Facts 
 • Crizotinib treatment of ALK-positive patients with non-small cell lung cancer (NSCLC) leads to a me-
dian progression-free survival of 9.7 months. 
 Novel Insights 
• Crizotinib retreatment of ALK-positive patients with secondary resistance to crizotinib after a drug 
holiday and conventional chemotherapy improves crizotinib sensitivity.
 • A good response to the new ALK inhibitor LDK 378 was obtained in a case of NSCLC after two treat-
ments with crizotinib. 





lecularly targeted therapy  [1–4] . Crizotinib is a new tyro-
sine kinase inhibitor (TKI) approved for the treatment of 
NSCLC with gene rearrangement of EML4 and ALK  [5] . 
Treatment with new TKIs, e.g. crizotinib, is often limited 
by the development of secondary crizotinib resistance, 
which ultimately limits the life expectancy of patients  [4] . 
Therefore, in case of acquired crizotinib resistance, new 
therapeutic strategies are needed. The following case re-
port describes successful management of crizotinib resis-
tance. 
 Case Report 
 A 70-year-old male patient (white, never-smoker) was diag-
nosed with adenocarcinoma [wild-type epidermal growth factor 
receptor (EGFR), EML4/ALK translocation positive] of the right 
upper lobe of the lung in February 2009. 
 The patient was initially diagnosed and treated at a commu-
nity hospital and was referred to our department following sec-
ond-line treatment for a second opinion. The stage at first diag-
nosis was cIIIA (cT2cN2cM0) and the patient was enrolled in a 
clinical trial and received neoadjuvant chemotherapy with three 
cycles of cisplatin and vinorelbin combined with cetuximab at 
cycle two and three. PET-CT then showed a partial remission, 
and resection was planned. Unfortunately, the thoracotomy re-
vealed inoperable mediastinal pleural infiltration and the proce-
dure was terminated. The patient was then treated with com-
bined radiochemotherapy with 54 Gy at the primary tumor site 
as well as two further cycles of cisplatin and vinorelbin. Follow-
ing a 5-month period of progression-free survival, a follow-up 
PET-CT showed recurrent tumor at the primary tumor site and 
along the right inner thoracic wall. Second-line systemic therapy 
with the EGFR-TKI erlotinib was initiated, but the tumor pro-
gressed after 4 months, causing clinically relevant multifocal cu-
taneous metastases, pleural carcinomatosis and total atelectasis 
of the right lung. A third-line systemic therapy with pemetrexed 
was initiated and the patient was referred to our center. Chemo-
therapy with pemetrexed was administered for two cycles. Prior 
to chemotherapy with pemetrexed, the primary tumor occupied 
most of the upper lobe with pleural and chest wall infiltration and 
obstruction of the intermediate bronchus. In addition, involve-
ment of subcarinal and bilateral axillary lymph nodes was de-
tected. Pemetrexed treatment induced shrinkage of the contra-
lateral lymph nodes; however, no relevant change in the remain-
ing sites involved was noticed. Therefore, a clinically meaningful 
response could not be established. Screening for the EML4-ALK 
gene rearrangement assessed by ALK FISH break apart test was 
positive, and therefore the patient was included in a clinical trial 
with crizotinib dosed at 250 mg twice daily. Treatment with 
crizotinib led to a partial remission with disappearance of the 
cutaneous metastases, better ventilation of the right lung and a 
reduction in exertional dyspnea. Following 6 months of crizo-
tinib, the primary tumor showed slight radiographic progres-
sion; however, the patient remained clinically stable on treat-
ment for an additional 3 months. Due to increasing cough and 
thoracic pain, crizotinib was then discontinued and the treat-
ment had to be changed to a conventional chemotherapy. Ac-
cording to the clinical data, both pemetrexed and docetaxel have 
a similar effect for second-line therapy of NSCLC. We considered 
both options, but the patient opted for pemetrexed instead of 
docetaxel, because of the more favorable toxicity profile of the 
former agent. Accordingly, the patient was treated with four cy-
cles of pemetrexed. This resulted in a partial response and im-
provement in symptoms. 
 Due to pemetrexed-associated neutropenia, pemetrexed was 
then discontinued and the patient was monitored clinically and 
radiologically. He remained stable for a period of 8 months before 
tumor progression prompted us to retreat with crizotinib.
 Retreatment with crizotinib led to a rapid and substantial im-
provement in the quality of life. CT confirmed significant remis-
sion of the intrathoracic tumor burden. Following 9 months of 
retreatment with crizotinib, the patient developed brain metasta-
sis. Crizotinib was discontinued and the patient was included in a 
study with LDK 378, a novel ALK inhibitor for crizotinib-resistant 
ALK-positive NSCLC. At this time, the patient remains under 
LDK 378 therapy and is in good general condition. Follow-up CT 
scans have shown regression of the intrathoracic tumor masses as 
well as the brain metastasis. Thus far, radiation of brain metastasis 
has not been performed.
 Discussion 
 EML4-ALK rearrangements result in an abnormal ex-
pression of ALK and subsequent activation of intracellu-
lar signaling pathways in a subset of NSCLC cells. Patients 
with ALK-positive tumors respond well to treatment with 
ALK inhibitors  [4, 6] . Crizotinib is an orally available, 
clinically well-tolerated TKI of ALK. Treatment of ALK-
positive NSCLC patients with crizotinib leads to a median 
progression-free survival of 9.7 months  [4, 7] . Unfortu-
nately, secondary resistance to crizotinib invariably de-
velops, limiting the life expectancy of these patients  [7, 8] . 
Our patient developed secondary crizotinib resistance 
with slow progression of his tumor after 9 months of 
crizotinib. Previous publications regarding the retreat-
ment of patients with secondary resistance to EGFR-TKIs 
suggest that a drug holiday and treatment with a conven-
tional chemotherapeutic may reestablish sensitivity to 
TKIs  [9, 10] . Although this strategy is well described for 
EGFR-TKIs, there is to date only one case report indicat-
ing that crizotinib retreatment of ALK-positive patients 
after a drug holiday and chemotherapy improves crizo-
tinib sensitivity  [11] . This case report illustrates that pa-
tients with secondary resistance to crizotinib can benefit 
from a range of therapeutic strategies, including drug hol-
iday, chemotherapy, retreatment with crizotinib and 
treatment with new ALK inhibitors in clinical trials. This 







new ALK inhibitor LDK 378 after two treatments with 
crizotinib. These observations illustrate the therapeutic 
options for crizotinib-resistant EML4-ALK-positive pa-
tients.
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